Blockchain Registration Transaction Record

Quantum BioPharma Advances MS Drug Lucid-MS, Targets Demyelination

Quantum BioPharma (NASDAQ: QNTM) advances MS drug Lucid-MS targeting demyelination, completes Phase 1, enters IND stage for Phase 2. Diversified portfolio includes unbuzzd(TM) wellness product. Learn more.

Quantum BioPharma Advances MS Drug Lucid-MS, Targets Demyelination

This news matters because Quantum BioPharma's focus on demyelination in multiple sclerosis offers a novel therapeutic approach that could address the root cause of disability progression, potentially improving outcomes for millions of MS patients worldwide. The company's diversified portfolio also provides multiple pathways to revenue, which may enhance its financial stability and long-term growth prospects.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xc910e3aa1b559b4ae2462a01e0d12aa94ff11e3c5da459fe3d1da2b0250193e4
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintfaceLsRa-fd3ca541897698af3bd47992a3a919c2